KURA
A chunky insider buy
Kura Oncology just got a nice little message from the top: the company’s president and CEO bought roughly 100,000 shares at $12.39 apiece, putting about $1.2 million of his own money to work.
That’s the kind of move investors tend to notice. When the person running the show is willing to buy stock in the open market, it can suggest management thinks the market is underappreciating the business — or at least that they’re feeling pretty good about what’s ahead.
Why you should care
Insider buying doesn’t guarantee the stock is about to moon. CEOs can buy for lots of reasons, and one purchase is not a magic eight ball. But large buys can still matter because they often signal confidence when the business story is already at a delicate stage.
For Kura, the key question is whether this is just a feel-good headline or a real hint that the company’s pipeline and prospects look better from inside the building than they do from your brokerage app.
Big picture
If you’re an investor, think of insider buying as management saying, “Hey, we’re willing to eat our own cooking.” It’s not a promise — but it’s usually not nothing either.